Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
$90.89
+0.3%
$91.41
$85.21
$101.31
$3.97B0.65148,297 shs92,989 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$822.14
-0.6%
$841.16
$711.40
$972.53
$783.91B0.343.15 million shs2.13 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$70.18
-2.2%
$82.78
$69.78
$148.15
$314.93B0.425.48 million shs7.96 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
-0.70%-1.79%-1.80%+4.03%-1.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.99%-1.25%-6.24%+4.12%+6.66%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.48%-9.08%-20.80%-18.15%-44.56%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8278 of 5 stars
2.45.03.34.03.42.51.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.8142 of 5 stars
4.45.01.70.02.50.04.4
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
0.00
N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7222.82% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.80
Moderate Buy$145.25106.97% Upside

Current Analyst Ratings Breakdown

Latest NVO, LLY, and IXJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/3/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
2/12/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight
2/3/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,029.00 ➝ $1,038.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,250.00 ➝ $1,190.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,000.00 ➝ $970.00
1/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$950.00
1/16/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$970.00
1/8/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Buy
(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
N/AN/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.31$13.40 per share61.34$15.05 per share54.63
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B1.08$3.25 per share21.57$4.64 per share15.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
N/AN/A28.77N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7170.2126.421.4023.51%85.24%16.19%5/1/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2921.3315.060.9034.81%84.68%26.29%5/1/2025 (Estimated)

Latest NVO, LLY, and IXJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
$1.291.42%N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.572.24%+25.26%47.72%N/A

Latest NVO, LLY, and IXJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55

Institutional Ownership

CompanyInstitutional Ownership
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
iShares Global Healthcare ETF stock logo
IXJ
iShares Global Healthcare ETF
N/A43.70 millionN/ANot Optionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable

Recent News About These Companies

Why Novo Nordisk Stock Dipped on Thursday
Novo Nordisk A/S stock logo
Top Growth Stocks To Follow Now - March 27th
Resolutions from the Annual General Meeting of Novo Nordisk A/S
1 Growth Stock Down 40% to Buy and Hold Forever
Brokerages Set Novo Nordisk A/S (NYSE:NVO) Price Target at $145.25
Novo Nordisk A/S stock logo
Growth Stocks Worth Watching - March 25th
Novo Nordisk A/S stock logo
Best Growth Stocks To Keep An Eye On - March 26th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
iShares Global Healthcare ETF stock logo

iShares Global Healthcare ETF NYSEARCA:IXJ

$90.89 +0.24 (+0.26%)
As of 04:10 PM Eastern

iShares Global Healthcare ETF (the Fund), formerly iShares S&P Global Healthcare Sector Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the S&P Global 1200 Healthcare Sector Index (the Index). The Index measures the performance of companies that Standards & Poor's Financial Services LLC (S&P) deems to be a part of the consumer staples sector of the economy. It is a subset of the S&P Global 1200 Index. Component companies include healthcare providers, biotechnology companies and manufacturers of medical supplies, advanced medical devices and pharmaceuticals. The Underlying Index consists of stocks of companies in countries, including Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Japan, the Netherlands, Switzerland, the United Kingdom and the United States. The Fund's investment advisor is BlackRock Fund Advisors (BFA).

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$822.14 -4.62 (-0.56%)
Closing price 03:59 PM Eastern
Extended Trading
$820.80 -1.33 (-0.16%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$70.18 -1.55 (-2.16%)
Closing price 03:59 PM Eastern
Extended Trading
$70.48 +0.31 (+0.44%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.